BioSpace News Archive

Aeterna Zentaris Inc. announced that on July 27, 2020, the Company received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550.

BrainsWay Ltd., a global leader in the advanced noninvasive treatment of brain disorders, announced that it will report its second quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2020.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has launched its proprietary AMPLIFY™ technology, which further increases the performance of its Prequel™ noninvasive prenatal screening test.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020.

- Oncolytics Biotech® Inc. announced that it will host a conference call and webcast on Tuesday, August 4, 2020, at 4:30 pm ET to discuss a corporate update and financial results for the second quarter of 2020.

Evogene Ltd., a leading artificial intelligence company targeting to revolutionize life-science product development across several market segments utilizing computational biology, announces that Ofer Haviv, Evogene’s President and CEO, will present at the Jefferies Virtual 2020 Industrials Conference taking place on August 5-6, 2020.

UCB to provide to Roche and Genentech exclusive, world-wide license to UCB’s UCB0107, an innovative anti-Tau antibody treatment

MONTREAL, July 29, 2020 /PRNewswire/ - Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has completed and filed its application to list the Company’s Class A shares on the OTCQB market in the United States.

Mantra Bio announced it has raised $25 million in a Series A financing to advance development of next generation, precision therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles.

Company Reports Second Quarter Revenues of $247.5 Million, GAAP Net Loss per Share of $0.19 and Diluted Non-GAAP Earnings per Share of $0.06